Albion Financial Group UT Sells 22,007 Shares of AbbVie Inc. $ABBV

Albion Financial Group UT lowered its position in AbbVie Inc. (NYSE:ABBV) by 47.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 23,971 shares of the company’s stock after selling 22,007 shares during the quarter. Albion Financial Group UT’s holdings in AbbVie were worth $5,477,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ABBV. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter valued at approximately $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC acquired a new stake in shares of AbbVie in the third quarter valued at approximately $33,000. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. Piper Sandler raised their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and outlets highlight AbbVie’s valuation and income appeal — calls that the shares look like a strong value play for long‑term investors given yield and discounted multiples. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Positive Sentiment: Seeking Alpha notes that while 2026 sets a high earnings bar, AbbVie’s shares remain attractive on valuation — a constructive view that can support the stock over time if guidance is met. AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
• Positive Sentiment: Comparisons with peers emphasize AbbVie’s attractive dividend profile versus Pfizer, supporting income‑focused demand for the stock. High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout
• Positive Sentiment: Analysts are watching Skyrizi and Rinvoq as the key growth drivers for Q1 immunology sales and market‑share recovery as Humira wanes — successful execution here would materially reinforce revenue trajectory. How Will Skyrizi and Rinvoq Shape AbbVie’s Q1 Immunology Sales?
• Neutral Sentiment: Sector news: two more drug firms are joining the TrumpRx pricing initiative — a broader pricing‑pressure story that could matter to big pharma if it expands, though the immediate impact on AbbVie is uncertain. Two more drug companies to officially launch on TrumpRx
• Neutral Sentiment: Miscellaneous industry piece (Regeneron/Kiniksa Arcalyst orphan‑drug coverage) is not AbbVie‑specific but contributes to wider sector investor interest in niche drug opportunities. Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market
• Negative Sentiment: AbbVie lowered its Q1 and full‑year 2026 earnings outlook after taking a $744M R&D charge — a direct negative to near‑term earnings expectations and a primary reason for the share weakness. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge
• Negative Sentiment: Market coverage notes the stock has underperformed peers and declined despite broader market gains — reinforcing short‑term selling pressure and investor caution. AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
• Negative Sentiment: Additional note on underperformance vs. competitors from MarketWatch — another datapoint traders use to justify reduced weight in the stock near term. AbbVie Inc. stock underperforms Monday when compared to competitors

Insider Activity

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.25% of the company’s stock.

AbbVie Stock Down 1.1%

Shares of ABBV stock opened at $206.62 on Tuesday. The firm has a market capitalization of $365.35 billion, a price-to-earnings ratio of 87.55, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a fifty day moving average of $221.30 and a 200-day moving average of $224.39.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s payout ratio is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.